User profiles for Elena Bartoloni

Elena Bartoloni Bocci

Ricercatore universitario, Universitā di Perugia
Verified email at unipg.it
Cited by 10144

Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients

…, P Pepe, L Quartuccio, R Priori, E Bartoloni… - …, 2014 - academic.oup.com
Objective. The aims of this study were to describe the clinical presentation of primary SS (pSS)
in a large cohort of patients by assessing the prevalence of the patient subgroups at high …

[HTML][HTML] COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy

C Perricone, E Bartoloni, R Bursi, G Cafaro… - Immunologic …, 2020 - Springer
SARS-CoV-2 infection is characterized by a protean clinical picture that can range from
asymptomatic patients to life-threatening conditions. Severe COVID-19 patients often display a …

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity …

…, S Bombardieri, R Priori, E Bartoloni… - Annals of the …, 2016 - ard.bmj.com
Objectives To define disease activity levels, minimal clinically important improvement (MCII)
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …

Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

…, S Bombardieri, G Valesini, E Bartoloni… - Annals of the …, 2015 - ard.bmj.com
Objectives To validate the two recently developed disease activity indexes for assessment of
primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) SS …

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

C Perricone, P Triggianese, E Bartoloni, G Cafaro… - Journal of …, 2020 - Elsevier
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an …

[HTML][HTML] Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study

…, N Ortego-Centeno, L Quartuccio, E Bartoloni… - Medicine, 2015 - journals.lww.com
Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial …

[HTML][HTML] Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course

…, L Quartuccio, R Gerli, E Bartoloni… - Journal of clinical …, 2019 - mdpi.com
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

[HTML][HTML] Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new

A Alunno, E Bartoloni, O Bistoni, G Nocentini… - Journal of Immunology …, 2012 - hindawi.com
Pathogenic mechanisms underlying the development of systemic lupus erythematosus (SLE)
are very complex and not yet entirely clarified. However, the pivotal role of T lymphocytes …

How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project)

…, S Praprotnik, D Sčne, E Bartoloni… - Clinical and …, 2018 - research.rug.nl
Objective. To evaluate the influence of the main immunological markers on the disease
phenotype at diagnosis in a large international cohort of patients with primary Sjogren's …

[PDF][PDF] Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

L Iaccarino, E Bartoloni, L Carli… - Clinical and …, 2015 - research.unipd.it
… Luca Iaccarino, Elena Bartoloni, Linda Carli, Fulvia Ceccarelli, Fabrizio Conti, Salvatore
De Vita, Gianfranco Ferraccioli, Mauro Galeazzi, Mariele Gatto, Roberto Gerli, Marcello …